AstraZeneca acquires Rigel's RA treatment for up to $1.2 billion
16 February 2010
Simon Varcoe
AstraZeneca is to pay the US-based
Rigel Pharmaceuticals $100 million up front for the exclusive worldwide rights to its late-stage oral treatment for rheumatoid arthritis (RA) R788 (fostamatinib disodium).
Rigel could receive up to $345 million on top of the up-front payment if the product...
Please Login to read the full article.
16 February 2010
Simon Varcoe
Rigel could receive up to $345 million on top of the up-front payment if the product...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
